NCT03874832View on ClinicalTrials.gov

A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 11, 2018

Primary Completion Date

November 7, 2018

Study Completion Date

November 7, 2018

Conditions

Migraine With AuraMigraine Without AuraMigraine

Interventions

DRUG

Dihydroergotamine

Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.

Trial Locations (1)

33126

Quotient Sciences Miami Inc., Miami

All Listed Sponsors

lead

Satsuma Pharmaceuticals, Inc.

INDUSTRY

NCT03874832 - A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects | Biotech Hunter | Biotech Hunter